Watson To Pay Elan $18M To Settle Naprelan IP Suit
Watson Pharmaceuticals Inc. will pay $18 million to Elan Corp. PLC to settle patent litigation over Watson's generic version of Naprelan, or naproxen sodium tablets, Watson announced Friday....To view the full article, register now.
Already a subscriber? Click here to view full article